Publications by authors named "T Skalidis"
Cefepime/zidebactam is in clinical development for the treatment of carbapenem-resistant Gram-negative infections. MICs of cefepime/zidebactam (1:1) and comparators against Enterobacterales (n = 563), Pseudomonas (n = 172) and Acinetobacter baumannii (n =181) collected from 15 Greek hospitals (2014-2018) were determined by reference broth microdilution method. The isolates exhibited high carbapenem resistance rates [(Enterobacterales (75%), Pseudomonas (75%) and A.
View Article and Find Full Text PDFInactivation of mgrB gene regulator and resistance to colistin is becoming endemic in carbapenem-resistant Klebsiella pneumoniae in Greece: A nationwide study from 2014 to 2017.
Int J Antimicrob Agents
April 2020
Introduction: In Greece, the spread of carbapenem-resistant Enterobacteriaceae in humans has led to the reintroduction of colistin as a therapeutic agent. Unfortunately, colistin resistance with different mechanisms has emerged. The present work aims to determine the prevalence of carbapenem and colistin resistance and the corresponding mechanisms in Klebsiella pneumoniae clinical isolates from Greece.
View Article and Find Full Text PDFIntroduction: A case of pneumococcal mastitis in a breast-feeding mother 6 months postpartum is described. Mastitis is usually caused by . A review of the literature from 1950 to March 2018 revealed only four other cases in which the causative organism was .
View Article and Find Full Text PDFArticle Synopsis
- TP-6076 is a synthetic antibiotic that targets bacterial protein synthesis, specifically tested against carbapenem-resistant Acinetobacter baumannii from 13 Greek hospitals.
- The study involved 121 bacterial isolates, where TP-6076 showed low minimum inhibitory concentrations (MICs) of 0.03 mg/L and 0.06 mg/L, indicating strong effectiveness.
- Compared to other antibiotics like tigecycline and minocycline, TP-6076 demonstrated superior activity against resistant strains, while its effectiveness remained consistent regardless of colistin susceptibility.
Background: Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases.
Methods: A collection of carbapenem-resistant Gram-negative bacteria isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline. Broth microdilution plates were used to determine MICs.